GenVec Inc (GNVC) - Financial and Strategic SWOT Analysis Review

GenVec Inc (GNVC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description A detailed description of the companys operations and business divisions.
- Corporate strategy Analysts summarization of the companys business strategy.
- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
- Company history Progression of key events associated with the company.
- Major products and services A list of major products, services and brands of the company.
- Key competitors A list of key competitors to the company.
- Key employees A list of the key executives of the company.
- Executive biographies A brief summary of the executives employment history.
- Key operational heads A list of personnel heading key departments/functions.
- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GenVec Inc (GenVec) focuses on the research and development of gene-based medicine. It develops therapeutics and vaccines using its proprietary adenovector gene delivery platform. The companys lead product, CGF166 is licensed to Novartis Institutes and is in Phase I/II for the treatment of hearing loss and balance disorders. Its therapeutics portfolio includes novel drugs for cancer, bleeding disorders; vaccines against infectious diseases, including herpes simplex virus (HSV), respiratory syncytial virus (RSV) and malaria. GenVec is also developing vaccines against foot-and-mouth disease (FMD) in cattle. The company also collaborates with leading companies and organizations to leverage its proprietary technology to prevent and treat significant health concerns. GenVec is head quartered in Gaithersburg, Maryland, the US.

GenVec Inc Key Recent Developments

Nov 04,2016: GenVec Reports Third Quarter 2016 Financial Results
Oct 05,2016: GenVec To Present At 2016 Cell & Gene Meeting On The Mesa
Aug 05,2016: GenVec Reports Second Quarter 2016 Financial Results
May 12,2016: GenVec Reports First Quarter 2016 Financial Results
Mar 09,2016: GenVec Reports Fourth Quarter and 2015 Year-End Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company




Section 1 - About the Company 5
GenVec Inc - Key Facts 5
GenVec Inc - Key Employees 6
GenVec Inc - Major Products and Services 7
GenVec Inc - History 8
GenVec Inc - Company Statement 9
GenVec Inc - Locations And Subsidiaries 11
Head Office 11
Section 2 Company Analysis 12
GenVec Inc - Business Description 12
GenVec Inc - Corporate Strategy 13
GenVec Inc - SWOT Analysis 14
SWOT Analysis - Overview 14
GenVec Inc - Strengths 14
GenVec Inc - Weaknesses 15
GenVec Inc - Opportunities 16
GenVec Inc - Threats 17
GenVec Inc - Key Competitors 18
Section 3 Company Financial Ratios 19
Financial Ratios - Capital Market Ratios 19
Financial Ratios - Annual Ratios 20
Performance Chart 22
Financial Performance 22
Financial Ratios - Interim Ratios 23
Financial Ratios - Ratio Charts 24
Section 4 Companys Lifesciences Financial Deals and Alliances 25
GenVec Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
GenVec Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
GenVec Inc, Recent Deals Summary 27
Section 5 Companys Recent Developments 28
Nov 04, 2016: GenVec Reports Third Quarter 2016 Financial Results 28
Oct 05, 2016: GenVec To Present At 2016 Cell & Gene Meeting On The Mesa 30
Aug 05, 2016: GenVec Reports Second Quarter 2016 Financial Results 31
May 12, 2016: GenVec Reports First Quarter 2016 Financial Results 33
Mar 09, 2016: GenVec Reports Fourth Quarter and 2015 Year-End Financial Results 34
Jan 20, 2016: GenVec Provides Investor Update 36
Section 6 Appendix 37
Methodology 37
Ratio Definitions 37
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables


GenVec Inc, Key Facts 5
GenVec Inc, Key Employees 6
GenVec Inc, Major Products and Services 7
GenVec Inc, History 8
GenVec Inc, Key Competitors 18
GenVec Inc, Ratios based on current share price 19
GenVec Inc, Annual Ratios 20
GenVec Inc, Annual Ratios (Cont...1) 21
GenVec Inc, Interim Ratios 23
GenVec Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
GenVec Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 26
GenVec Inc, Recent Deals Summary 27
Currency Codes 37
Capital Market Ratios 37
Equity Ratios 38
Profitability Ratios 38
Cost Ratios 39
Liquidity Ratios 39
Leverage Ratios 40
Efficiency Ratios 40

List Of Figures


GenVec Inc, Performance Chart (2012 - 2016) 22
GenVec Inc, Ratio Charts 24
GenVec Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 25
GenVec Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 26

GenVec, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

GenVec, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines GenVec, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports

USD 350 View Report

GenVec Inc (GNVC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GenVec Inc (GenVec) focuses on the research and development of gene-based medicine. It develops therapeutics and vaccines using its proprietary adenovector gene delivery platform. The companys lead product, CGF166 is

USD 250 View Report

GenVec Inc (GNVC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GenVec Inc (GenVec) focuses on the research and development of gene-based medicine. It develops therapeutics and vaccines using its proprietary adenovector gene delivery platform. The companys lead product, CGF166 is

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available